Introduction {#s1}
============

Nonalcoholic fatty liver disease (NAFLD) is characterized by the presence of extra fat in the liver, exceeding 5--10% of liver weight. Most patients with NAFLD have increased liver fat only (simple steatosis). Some of the patients develop hepatic inflammation, a condition known as nonalcoholic steatohepatitis (NASH), and up to 20% of patients experience progressive hepatic fibrosis and may eventually progress to liver cirrhosis or failure and even hepatocellular carcinoma.[@b1] Precautionary procedures for NAFLD screening and diagnosis should be taken due to the disturbing increase in the NAFLD worldwide frequency and the moderate development in finding successful medicinal treatment. Primary assessment of early stages of fatty liver requires abdominal ultrasonographic examination, measurement of lipid profile and liver functions, exclusion of hepatitis B and C and alcohol toxicity, and screening for insulin resistance (IR).[@b2]

The gold standard for NASH diagnosis is liver biopsy. This procedure, however, is invasive, overpriced, and associated with rare but potentially risky complications and sampling errors; hence, it is not appropriate as a screening tool.[@b3] One of the imaging techniques which is used as noninvasive diagnostic test for NAFLD is ultrasonography, by which the incidence and severity of fatty liver are measured by grading of fatty liver (Grade 1, 2 and 3) according to the hyperechogenicity of the liver tissue, the divergence between liver and diaphragm and the visibility of vascular structures.[@b1],[@b4],[@b5]

NAFLD pathogenesis involves a multi-hit process. Steatosis which is believed to be initiated by IR is considered as the first hit, while changes in cytokines and oxidative stress are considered as the second hit, resulting in disease progression.[@b6] Cytokines are produced by T helper cells, which are categorized as T helper 1 cells, secreting pro-inflammatory cytokines such as interleukin (IL)-18,[@b7] and T helper 2 cells, secreting anti-inflammatory cytokines such as IL-10.[@b8] Several lines of evidence support a role for IL-18 in the pathogenesis of IR and NAFLD,[@b6] while only a few studies have examined the role of IL-10 in NAFLD pathogenesis.[@b3] Beside the insulin-sensitizing effects of IL-10,[@b9] an imbalance between pro- and anti- inflammatory cytokines has been found in the context of NASH in the liver.[@b10]

The plasma cell membrane glycoprotein, plasma cell antigen-1 (PC-1), is a type II transmembrane glycoprotein associated with the insulin receptor on the cell surface and inhibits insulin signaling.[@b11] It has been reported that PC-1 is significantly associated with progression of NAFLD.[@b12]

Therefore, we aimed to evaluate the significance of some biomarkers as well as ultrasonographic and anthropometric findings in differentiating between NAFLD grades, since most previous studies[@b13]--[@b17] have been more concerned with studying NAFLD patients without classifying them ultrasonographically into grades.

Methods {#s2}
=======

Subjects {#s2-1}
--------

From January 2015 to October 2015, a total of 87 non-diabetic (blood sugar \< 126 mg/dL) obese patients with NAFLD, who have never taken any medication for diabetes, and 47 control subjects were recruited from the Liver Clinic, Medical Service Unit at the National Research Center. All patients and controls were examined ultrasonographically. Written informed consent was obtained from all subjects and this study was approved by the Human Ethics Committee of the National Research Center (Code No. 14075).

Exclusion criteria {#s2-2}
------------------

Patients with hepatitis B or hepatitis C infection, diabetes, splenectomy, cholestasis, coronary artery disease or pregnancy were excluded. Patients with alcohol consumption, cigarette smoking and use of amiodarone, corticosteroids, tamoxifen or methotrexate were also excluded.

Ultrasound (US) examination {#s2-3}
---------------------------

US examinations were performed by the same physician using SonoAce R5 (6 MHz; Samsung). Examination of all the patients was done for diagnosing and classifying grades of NAFLD according to Kakrani *et al*.[@b4] as follows: **Grade-0 (control group):** This group included 20 females and 27 males with normal findings on US; their ages ranged from 25 to 57 years, and they were age- and sex-matched with patients ([Fig. 1a](#f01){ref-type="fig"}).**Grade-I (mild NAFLD):** This group included 16 females and 15 males, in which the US showed fine diffuse increase in echogenicity of liver texture; their ages ranged from 25 to 58 years ([Fig. 1b](#f01){ref-type="fig"}).**Grade-II (moderate NAFLD):** This group included 20 females and 6 males with diffuse increased coarse echogenicity of liver texture and with mild attenuation of US sound beams; their ages ranged from 25 to 60 years ([Fig. 1c](#f01){ref-type="fig"}).**Grade-III (severe NAFLD):** This group included 22 females and 8 males with diffuse increased coarse echogenicity of liver texture, resulting in poor visibility of portal vein radicle walls and right hemi diaphragm; their ages ranged from 25 to 60 years ([Fig. 1d](#f01){ref-type="fig"}).

![Grades of fatty liver on visual analysis.\
Ultrasound image shows (a) normal liver echogenicity, (b) grade 1 fatty liver with increased liver echogenicity, (c) grade 2 fatty liver with the echogenic liver obscuring the echogenic walls of the portal venous branches, and (d) grade 3 fatty liver in which the diaphragmatic outline is obscured.](JCTH-5-109-g001){#f01}

Liver size was demonstrated by measuring distance between upper and lower borders in the mid-clavicular line. Liver parenchyma was examined with sagittal as well as longitudinal guidance of the probe and completed by lateral and intercostal views.[@b18] Transverse scanning was performed to assess the maximum subcutaneous fat thickness (SFT), which was defined as the distance between the external face of the recto-abdominal muscle and the internal layer of the skin, and visceral fat thickness (VFT), which was defined as the distance between the anterior wall of the aorta and the internal layer of the recto-abdominal muscle perpendicular to the aorta.[@b19]

Anthropometric measurements {#s2-4}
---------------------------

Body mass index (BMI) was determined by dividing weight by squared height (kg/m^2^). Waist circumference (WC) was obtained from each subject by measuring at the midpoint between the lower rib margin and the iliac crest using a conventional tape graduated in centimeters (cm). Hip was measured as the greatest abdominal circumference at the level of greater trochanters. Waist-to-hip ratio was calculated by dividing the waist by the hip circumference.

Samples collection {#s2-5}
------------------

Blood samples (4 mL) were drawn in the morning after 12 hours fasting then divided into three portions. The first portion (2 mL) was left to clot for 30 min at room temperature and then centrifuged at 3000 rpm for serum separation to determine the levels of insulin, IL-10, AST, ALT, albumin, total protein and lipid profile parameters. The second portion (1 mL) was collected in EDTA-containing tubes and centrifuged at 3000 rpm for plasma separation to determine the levels of IL-18 and PC-1. The third portion (1 mL) was collected in a mixture of EDTA and fluoride and centrifuged at 3000 rpm for plasma separation to determine fasting plasma glucose.

Biochemical analyses {#s2-6}
--------------------

Fasting plasma glucose test was performed according to Heinz and Beushausen[@b20] using the kit supplied by Stanbio Laboratory (USA). Plasma IL-18 levels were assayed by an enzyme-linked immunosorbent assay (ELISA) kit purchased from Wuhan EIAab Science Company (China). Plasma PC-1 level was determined quantitatively by an ELISA kit purchased from Glory Science Company (USA). Serum insulin concentration was determined by an ELISA kit purchased from Monobind Company (USA). Serum interleukin-10 concentration was determined quantitatively by an ELISA kit obtained from R&D Systems Company (USA). Serum AST and ALT activities were determined according to Bermeyer and Horder[@b21] using a kit obtained from Human Company (Germany). Serum albumin concentration was determined colorimetrically by the BCG-method[@b22] using a kit obtained from Human Company. Serum total protein concentration was determined colorimetrically by the Biuret method[@b23] using a kit obtained from Human Company. Lipid profile (total cholesterol, triglycerides, high-density lipoprotein (HDL)-cholesterol) kits were obtained from Stanbio Laboratory. Serum total cholesterol was determined by an enzymatic colorimetric method,[@b24] while serum triglycerides were determined by an enzymatic colorimetric method according to Fredrickson *et al*.[@b25] HDL-cholesterol was determined according to Finley *et al*.,[@b26] while low-density lipoprotein (LDL)-cholesterol was calculated according to the Friedewald *et al*.[@b27] equation: $$\begin{array}{l}
\text{LDL-cholesterol~(mg/dL)} \\
\text{\quad\quad=~total~cholesterol-HDL-triglycerides/5} \\
\end{array}$$

The IR index was assessed by the homoeostasis model assessment (HOMA)-IR, calculated by the following equation by Matthews *et al*.[@b28] $$\text{HOMA-IR} = \text{glucose}\left( \text{mg/dL} \right)\text{×~insulin}\left( \text{mIU/mL} \right)\text{/}22.5$$

Statistical analyses {#s2-7}
--------------------

The Statistical Package for the Social Sciences software \[version 17.0; SPSS, USA\] was used. Normally distributed continuous variables were expressed as mean (± SE); qualitative variables were presented as proportions. Quantitative variables were compared using one-way ANOVA; the least significant difference test was used for multiple post-hoc comparisons. On the other hand, qualitative variables were compared using the chi-square \[X^2^\] test or Fischer′s exact test. Variables which were significant on univariate analysis were included in the multivariate analysis and independent variables with *p* \> 0.1 were excluded sequentially from the models. The odds ratios and associated *p*-values of the remaining variables are reported. Two-sided *p*-values ≤ 0.05 were considered statistically significant.

Results {#s3}
=======

There were significant differences in sex distribution (males) among grade 2 and grade 3 when compared to grade 0 ([Table 1](#t01){ref-type="table"}). There were significant differences in age, BMI, waist and hip circumference, diastolic and systolic blood pressure, size of liver and spleen, subcutaneous fat (SCF) and visceral fat (VF) in different NAFLD grades when compared to controls ([Table 1](#t01){ref-type="table"}).

###### Demographic characteristics of NAFLD patients and control subjects

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable\          Grade 0 (*n* = 47)   Grade 1 (*n* = 31)                                                                             Grade 2 (*n* = 26)                                                                                                                                                            Grade 3 (*n* = 30)                                                                                                                                                              
  Groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ------------------ -------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  Age (years)        35.80 ± 1.45         44.51 ± 1.81[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}    51.12 ± 2[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}^,^[^b^](#table1fn1){ref-type="table-fn"}[\*\*](#table1fn2){ref-type="table-fn"}      59.4 ± 1.86[^abc^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                 

  Sex                Male                 27 (57.4%)                                                                                     15 (48.4%)                                                                                                                                                                    6 (23.1%)[^a^](#table1fn1){ref-type="table-fn"}[\*\*](#table1fn2){ref-type="table-fn"}                                                                                          9 (30.0%)[^a^](#table1fn1){ref-type="table-fn"}[\*](#table1fn2){ref-type="table-fn"}

  Female             20 (42.6%)           16 (51.6%)                                                                                     20 (76.9%)                                                                                                                                                                    21 (70.0%)                                                                                                                                                                      

  BMI (kg/dL)        22.70 ± 0.24         32.49 ± 0.7[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}     39.05 ± 1.13[^ab^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                               43.90 ± 1.15[^abc^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                

  DBP (mmHg)         111.49 ± 1.79        126.77 ± 2.71[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}   125.96 ± 2.80[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                  126.4 ± 2.35[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                     

  SBP (mmHg)         72.98 ± 1.65         84.03 ± 2.34[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}    85.38 ± 1.61 [^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                  81.1 ± 1.84[^a^](#table1fn1){ref-type="table-fn"}[\*\*](#table1fn2){ref-type="table-fn"}                                                                                        

  WC (cm)            81.55 ± 0.81         102.58 ± 1.57[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}   108.88 ± 2.06[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}^,^[^b^](#table1fn1){ref-type="table-fn"}[\*](#table1fn2){ref-type="table-fn"}    112.13 ± 2.46[^ab^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                

  HC (cm)            100.74 ± 1.02        114.22 ± 0.96[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}   123.76 ± 2.36[^ab^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                              124.53 ± 1.63[^ab^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                

  W/H ratio          0.81 ± .006          0.89 ± .013[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}     0.88 ± .013[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                    0.89 ± .012[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                      

  Liver size (cm)    13.52 ± 0.203        14.79 ± 0.179[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}   16.27 ± 0.175[^ab^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                              18.04 ± 0.178[^abc^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                               

  Spleen size (cm)   9.14 ± 0.201         10.51 ± 0.388[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}   11.05 ± 0.194[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                  10.99 ± 0.223[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                    

  SCF (cm)           1.20 ± 0.05          1.72 ± 0.105[^a^](#table1fn1){ref-type="table-fn"}[\*\*](#table1fn2){ref-type="table-fn"}      2.29 ± 0.167[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}^,^[^b^](#table1fn1){ref-type="table-fn"}[\*\*](#table1fn2){ref-type="table-fn"}   2.69 ± 0.203[^ab^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}^,^[^c^](#table1fn1){ref-type="table-fn"}[\*](#table1fn2){ref-type="table-fn"}   

  VF (cm)            3.09 ± 0.203         5.71 ± 0.342[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}    6.04 ± 0.355[^a^](#table1fn1){ref-type="table-fn"}[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                   8.22 ± 0.260[^abc^](#table1fn1){ref-type="table-fn"}^:^[\*\*\*](#table1fn2){ref-type="table-fn"}                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; WC, waist circumference; HC, hip circumference; W/H, waist/hip; SCF, subcutaneous fat; VF, visceral fat.

Data are presented as mean ± SE, a: significant difference from grade 0, b: significant difference from grade 1, c: significant difference from grade 2.

^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001.

Age and BMI were significantly higher in grade 2 and grade 3 than in grade 1. It is worth noting that age and BMI were significantly higher in grade 3 than in grade 2. Concerning systolic blood pressure and diastolic blood pressure, there were no significant differences among the NAFLD grades. WC and hip circumference were significantly higher among grade 2 and grade 3 compared to grade 1. Liver size and SCF were significantly higher among grade 2 and grade 3 patients compared to grade 1 patients, while grade 3 patients showing more highly significant differences than grade 2 ([Table 1](#t01){ref-type="table"}).

Insulin, HOMA-IR and fasting plasma glucose were significantly higher in NAFLD grades than in grade 0. In addition, insulin and HOMA-IR were significantly higher in grade 3 than grade 1. On the other hand, no significant differences (*p* \> 0.05) were found in AST, ALT albumin or total protein levels between the NAFLD grades (*p* \> 0.05) ([Table 2](#t02){ref-type="table"}).

###### Biochemical data among NAFLD grades and controls

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable\                   Grade 0 (*n* = 47)   Grade 1 (*n* = 31)                                                                              Grade 2 (*n* = 26)                                                                              Grade 3 (*n* = 30)
  Groups                                                                                                                                                                                                                                           
  --------------------------- -------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  FBG (mg/dL)                 83.90 ± 1.13         95.14 ± 2.37[^a^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}       98.13 ± 5.38[^a^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}       103.66 ± 4.33[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}

  Insulin (mIU/mL)            6.56 ± 0.24          8.74 ± 0.67[^a^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}          10.55 ± 0.94[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}     11.16 ± 1.01[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}^,^[^b^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}

  HOMA-IR index               1.33 ± 0.05          1.99 ± 0.14[^a^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}        2.5 ± 0.24[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}       2.82 ± 0.28[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}^,^[^b^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}

  Albumin (g/dL)              4.24 ± 0.11          4.3 ± 0.11                                                                                      4.38 ± 0.18                                                                                     4.41 ± 0.12

  Total protein (g/dL)        7.69 ± 0.14          8.01 ± 0.17                                                                                     7.80 ± 0.24                                                                                     7.87 ± 0.23

  AST (IU/L)                  14.11 ± 1.16         15.3 ± 0.70                                                                                     15.9 ± 1.81                                                                                     17.4 ± 1.07

  ALT (IU/L)                  13.36 ± 1.60         14.1 ± 0.86                                                                                     15.3 ± 1.34                                                                                     16.04 ± 0.68

  Total cholesterol (mg/dL)   179.37 ± 4.11        250.01 ± 10.41[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}   261.97 ± 9.25[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}    289.14 ± 10.36[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}^,^[^b^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}^,^[^c^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}

  Triacylglycerol (mg/dL)     106.81 ± 3.05        186.93 ± 12.63[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}   213.23 ± 11.71[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}   255.43 ± 10.99[^ab^](#table2fn1){ref-type="table-fn"}^:^[\*\*\*](#table2fn2){ref-type="table-fn"}^,^[^c^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}

  HDL-cholesterol (mg/dL)     72.10 ± 3.25         53.81 ± 2.37[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}     50.15 ± 4.61[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}     40.66 ± 1.37[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}^,^[^b^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}^,^[^c^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}

  LDL-cholesterol (mg/dL)     85.90 ± 5.40         158.81 ± 9.97[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}    169.16 ± 9.67[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}    197.40 ± 10.48[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}^,^[^b^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}^,^[^c^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}

  VLDL (mg/dL)                21.36 ± 0.61         37.38 ± 2.52[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}     42.65 ± 2.34[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}     51.07 ± 2.19[^ab^](#table2fn1){ref-type="table-fn"}^:^[\*\*\*](#table2fn2){ref-type="table-fn"}^,^[^c^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}

  IL-18 (pg/mL)               10.54 ± 0.55         11.47 ± 0.61                                                                                    10.55 ± 0.94                                                                                    14.81 ± 1.62[^a^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}^,^[^b^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}^,^[^c^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}

  IL-10 (pg/mL)               4.87 ± 0.205         7 ± 0.688[^a^](#table2fn1){ref-type="table-fn"}[\*\*\*](#table2fn2){ref-type="table-fn"}        5.38 ± 0.412[^b^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}         5.19 ± 0.411[^b^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}

  PC-1 (pg/mL)                5 ± 0.27             8.45 ± 1.51[^a^](#table2fn1){ref-type="table-fn"}[\*\*](#table2fn2){ref-type="table-fn"}        6.52 ± 1.18                                                                                     5.45 ± 0.77[^b^](#table2fn1){ref-type="table-fn"}[\*](#table2fn2){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: FPG, fasting plasma glucose; HOMA-IR, homoeostasis model assessment-insulin resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IL-18, interleukin-18; IL-10, interleukin-10; PC-1, plasma cell antigen-1.

Data are presented as mean ± SE, a: significant difference from grade 0, b: significant difference from grade 1, c: significant difference from grade 2.

^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001.

In different NAFLD grades, lipid profile parameters (total cholesterol, triacylglycerol, LDL-cholesterol and very low-density lipoprotein (VLDL)-cholesterol) were significantly higher when compared to grade 0, while there was significant decrement in HDL between NAFLD grades and grade 0. However, comparing the different NAFLD grades to each other, there was significant differences in the lipid profile parameters ([Table 2](#t02){ref-type="table"}).

IL-18 was significantly higher in grade 3 compared to the other grades. On the other hand, IL-10 was significantly higher in grade 1 compared to grades 0, 2 and 3. PC-1 level was significantly higher in grade 1 compared to both grade 0 and grade 3 ([Table 2](#t02){ref-type="table"})

Receiver operating characteristic (ROC) curve was constructed to determine the threshold value for optimal sensitivity (≥80%) and best values for area under the curve (AUC ≥0.5) in order to be able to differentiate between the different NAFLD grades. Different studied parameters, like the anthropometric (WC, hip circumference and BMI) and ultrasonographic parameters, lipid profile, IL-18, PC-1 and HOMA-IR have both optimal sensitivity (≥80%) and best values for AUC ≥0.5, and could differentiate between the different NAFLD grades as shown in [Tables 3](#t03){ref-type="table"}, [4](#t04){ref-type="table"}, [5](#t05){ref-type="table"} and [6](#t06){ref-type="table"}.

###### ROC results for WC, hip circumference and BMI

                            Grade 0 & Grade 1   Grade 0 & Grade 2   Grade 0 & Grade 3   Grade 1 & Grade 2   Grade 1 & Grade 3                                                                                                          
  ------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- --------- ------------ --------- --------- -------------- -------------- -------------- -------------- --------------
  AUC                       0.98                0.94                0.99                0.99                0.96                0.99      0.98         0.99      1         0.68           0.81           0.83           0.51           0.94
  Cut-off value             93                  106                 24.9                94                  109                 24.9      91           109       26.2      100            116            35.2           0.84           38.5
  Sensitivity               90.3                96.8                100                 92.3                96.2                100       93.3         100       100       88.5           80.8           80.8           83.3           83.3
  Specificity               97.9                82.9                97.9                100                 91.5                97.9      93.6         91.5      100       45.2           74.2           77.4           29.03          93.6
  PLR                       42.5                5.7                 47                                      11.3                47        14.6         11.8                1.6            3.13           3.6            1.17           12.9
  NLR                       0.099               0.039               0.00                0.077               0.042               0.00      0.071        0.00      0.00      0.26           0.26           0.25           0.57           0.18
  PPV                       96.6                78.9                96.9                100                 86.2                96.3      90.3         88.2      100       57.5           72.4           75             53.2           92.6
  NPV                       93.9                97.5                100                 95.9                97.7                100       95.7         100       100       82.4           82.1           82.8           64.3           85.3
  Accuracy                  94.9                88.5                98.7                97.3                93.1                98.6      93.5         94.8      100       64.9           77.2           78.9           55.7           88.5
  *p*-value                 \<0.0001            0.012               \<0.0001            0.88                \<0.0001                                                                                                                   
  95% confidence interval   0.92--0.99          0.86--0.98          0.95--1             0.93--1             0.88--0.99          0.95--1   0.92--0.99   0.93--1   0.95--1   0.544--0.789   0.683--0.901   0.712--0.919   0.380--0.642   0.851--0.986

Abbreviations: WC, waist circumference; HC, hip circumference; BMI, body mass index; W/H, waist to hip; AUC, area under the curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.

###### ROC results for IL-18, PC-1 and HOMA-IR index

                            Grade 0 & Grade 1   Grade 0 & Grade 2   Grade 0 & Grade 3   Grade 1 & Grade 2   Grade 1 & Grade 3   Grade 2 & Grade 3                  
  ------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------- --------------
  AUC                       0.59                0.58                0.53                0.89                0.51                0.56                0.57           0.69
  Cut-off value             7.5                 3.8                 3.8                 1.7                 7                   7                   6              9.2
  Sensitivity               100                 92.3                90                  83.3                92.3                96.7                90             80
  Specificity               23.4                27.7                27.7                91.5                29.03               29.03               23.08          61.5
  PLR                       1.3                 1.28                1.24                9.8                 1.3                 1.4                 1.17           2.08
  NLR                       0.000               0.28                0.36                0.18                0.26                0.11                0.43           0.33
  PPV                       46.3                41.4                44.3                86.2                52.2                56.9                57.4           70.6
  NPV                       100                 86.7                81.2                89.6                81.8                90                  66.7           72.7
  Accuracy                  53.8                50.7                51.9                88.3                57.9                62.3                58.9           71.4
  *p*-value                 0.145               0.201               0.637               \<0.0001            0.896               0.386               0.354          0.009
  95% confidence interval   0.476--0.704        0.463--0.699        0.413--0.645        0.8--0.951          0.374--0.645        0.430--0.690        0.430--0.701   0.553--0.807

Abbreviations: ROC, receiver operating characteristic; IL-18, interleukin-18; PC-1, plasma cell antigen-1; HOMA-IR, homoeostasis model assessment-insulin resistance; AUC, area under the curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.

###### ROC results for ultrasonography findings

                            Grade 0 & Grade 1   Grade 0 & Grade 2   Grade 0 & Grade 3   Grade 1 & Grade 2   Grade 1 & Grade 3   Grade 2 & Grade 3                                                                                                                                            
  ------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------ ------------ --------- ------------ ------------ ------------ --------- ------------ ------------ ------------ ------------ ------------
  AUC                       0.72                0.97                0.87                0.9                 0.9                 1                   0.84         0.98         0.99      0.87         0.72         0.53         0.99      0.82         0.86         0.92         0.83         0.59
  Cut-off value             9.3                 15.2                9.7                 1.5                 3.4                 15.7                9.3          1.5          5         15.7         10           3            16.3      1.6          6.7          16.5         6.7          1.6
  Sensitivity               80.7                88.5                92.3                80.8                96.2                100                 90           100          100       80.8         92.3         100          100       100          90           100          90           100
  Specificity               63.8                95.7                72.3                85.1                72.3                100                 63.8         85.1         95.7      83.9         58.1         12.9         96.8      58.1         70.97        69.2         73.1         26.9
  PLR                       2.23                20.8                3.3                 5.4                 3.5                                     2.5          6.7          23.5      5.01         2.2          1.15         31        2.4          3.1          3.3          3.3          1.4
  NLR                       0.3                 0.12                0.11                0.23                0.05                0.00                0.16         0.00         0.00      0.23         0.13         0.00         0.00      0.00         0.14         0.00         0.14         0.00
  PPV                       59.5                92                  64.9                75                  65.8                100                 61.4         81.1         93.8      80.8         64.9         49.1         96.8      69.8         75           78.9         79.4         61.2
  NPV                       83.3                93.7                94.4                88.9                97.1                100                 90.9         100          100       83.9         90           \`100        100       100          88           100          86.4         100
  Accuracy                  70.5                93.1                79.4                83.6                80.8                100                 74.04        90.9         97.4      82.5         73.7         52.6         98.4      78.7         80.3         85.7         82.1         66.1
  *p*-value                 \<0.001             \<0.0001            0.002               0.68                \<0.0001            0.27                                                                                                                                                         
  95% confidence interval   0.61--0.81          0.89--0.99          0.76--0.93          0.81--0.96          0.81--0.96          0.95--1             0.73--0.91   0.92--0.99   0.94--1   0.76--0.96   0.58--0.83   0.39--0.67   0.93--1   0.70--0.91   0.75--0.94   0.82--0.98   0.70--0.92   0.45--0.72

Abbreviations: ROC, receiver operating characteristic; SS, spleen size; LS, liver size; SCF, subcutaneous fat; VF, visceral fat; AUC, area under the curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.

###### ROC results for lipid profile

                            Grade 0 & Grade 1   Grade 0 & Grade 2   Grade 0 & Grade 3   Grade 1 & Grade 2   Grade 1 & Grade 3   Grade 2 & Grade 3                                                                                                        
  ------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------ --------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  AUC                       0.89                0.74                0.87                0.94                0.96                0.77                0.92         1         0.89         0.58         0.62         0.79         0.82         0.68         0.60
  Cut-off value             200.6               61.8                91.4                223.5               136                 59.03               116.3        157.8     55           219.8        171.3        189.6        47.2         188.8        51.7
  Sensitivity               83.9                87.1                90.3                80.8                88.5                80.8                88.5         100       96.7         84.6         80.8         90           86.7         90           93.3
  Specificity               82.9                70.2                70.2                95.7                95.7                70.2                78.7         100       76.6         35.5         48.4         54.8         67.7         42.3         42.3
  PLR                       4.9                 2.9                 3.03                18.9                20.8                2.7                 4.2                    4.13         1.3          1.6          1.99         2.7          1.6          1.6
  NLR                       0.19                0.18                0.14                0.2                 0.12                0.27                0.15         0.00      0.044        0.43         0.4          0.18         0.2          0.24         0.16
  PPV                       76.5                65.9                66.7                91.3                92                  60                  69.7         100       72.5         52.4         56.8         65.9         72.2         64.3         65.1
  NPV                       88.6                89.2                91.7                90                  93.7                86.8                92.5         100       97.3         73.3         75           85           84           78.6         84.6
  Accuracy                  83.3                76.9                78.2                90.4                93.1                73.9                82.2         100       84.4         57.9         63.2         72.14        77.05        67.9         69.7
  *p*-value                 \<0.0001            0.295               0.102               \<0.0001            0.01                0.212                                                                                                                    
  95% confidence interval   0.79--0.95          0.63--0.84          0.77--0.93          0.86--0.98          0.89--0.99          0.66--0.86          0.83--0.97   0.95--1   0.79--0.95   0.44--0.71   0.49--0.75   0.67--0.88   0.69--0.90   0.55--0.80   0.46--0.73

Abbreviations: ROC, receiver operating characteristic; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; AUC, area under the curve; PLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.

[Table 7](#t07){ref-type="table"} presents the results of logistic regression, by which WC, hip circumference, waist to hip ratio, IL-10, PC-1, HOMA-IR, ultrasonographic findings and lipid profile were associated with grade 1 due to their significant *p*-values (≤0.05). Moreover, WC, hip circumference, waist to hip ratio, HOMA-IR, ultrasonographic findings and lipid profile were found to be associated with grade 2 due to their significant *p*-values (\<0.01). WC, hip circumference, waist to hip ratio, IL-18,HOMA-IR, ultrasonographic findings (except for liver size) and lipid profile (except for triglycerides) were found to be associated with grade 3 due to their significant *p*-values (\<0.01). Furthermore, by multivariate analysis, HOMA-IR showed a significant *p*-value (\<0.01) when combined with IL-10, IL-18 or PC-1, or combined all together. Thus, there were associations between these parameters in the different NAFLD grades (grade 1, grade 2 and grade 3).

###### Variables associated with different NAFLD grades (multivariate analysis)

  Parameter                           Grade 1   Grade 2    Grade 3                                                                                      
  ----------------------------------- --------- ---------- ---------- ---------- ------- ---------- ---------- ---------- ------- ---------- ---------- ----------
  WC                                  0.001     1.494      1.217      1.834      0.002   1.513      1.168      1.960      0.001   1.384      1.141      1.679
  HC                                  0.001     1.407      1.213      1.633      0.001   1.315      1.156      1.497      0.001   1.592      1.213      2.088
  W/H ratio                           0.001     3.19E+13   9.81E+06   1.04E+20   0.001   1.70E+11   2.60E+05   1.11E+17   0.001   7.38E+13   1.69E+07   3.22E+20
  BMI                                 0.068     18.514     0.805      425.530    0.150   12.249     0.404      371.450    0.993   181.597    0.001      .
  Liver size                          0.001     2.486      1.502      4.116      0.001   14.204     3.738      53.974     0.990   1.46E+14   0.00E+00   .
  Spleen size                         0.003     1.865      1.233      2.820      0.001   4.465      2.160      9.230      0.001   2.978      1.793      4.949
  SCF                                 0.001     12.853     3.283      50.322     0.001   44.494     6.368      310.899    0.005   1.43E+05   3.89E+01   5.25E+08
  VF                                  0.001     2.410      1.647      3.528      0.001   3.034      1.843      4.995      0.001   9.233      2.535      33.634
  Cholesterol                         0.001     1.051      1.027      1.075      0.001   1.073      1.037      1.110      0.001   1.056      1.027      1.086
  Triglycerides                       0.001     1.050      1.026      1.075      0.001   1.081      1.037      1.128      0.957   1.32E+04   0.00E+00   1.7E+153
  HDL                                 0.001     0.951      0.924      0.978      0.001   0.957      0.933      0.982      0.001   0.889      0.841      0.940
  LDL                                 0.001     1.035      1.020      1.051      0.001   1.047      1.025      1.069      0.001   1.039      1.023      1.056
  VLDL                                0.001     1.278      1.137      1.436      0.001   1.476      1.197      1.821      0.952   1.48E+24   0.00E+00   .
  IL-10                               0.005     1.478      1.125      1.942      0.218   1.195      0.900      1.588      0.434   1.109      0.856      1.435
  IL-18                               0.268     1.073      0.947      1.217      0.992   1.001      0.891      1.124      0.016   1.139      1.024      1.267
  PC-1                                0.046     1.164      1.003      1.350      0.183   1.117      0.949      1.314      0.540   1.049      0.899      1.225
  HOMA-IR index                       0.001     8.751      2.792      27.428     0.001   20.894     3.667      119.068    0.001   25.485     5.264      123.376
  IL-10, IL-18                        0.007     1.019      1.005      1.033      0.452   1.005      0.992      1.019      0.020   1.017      1.003      1.031
  IL-10, PC-1                         0.002     1.045      1.016      1.075      0.106   1.023      0.995      1.051      0.579   1.009      0.979      1.039
  IL-18, PC-1                         0.015     1.017      1.003      1.032      0.352   1.005      0.995      1.015      0.059   1.015      0.999      1.030
  IL-10, HOMA-IR index                0.001     1.419      1.193      1.687      0.001   1.321      1.125      1.552      0.001   1.334      1.137      1.565
  IL-18, HOMA-IR index                0.001     1.107      1.041      1.177      0.003   1.089      1.029      1.153      0.001   1.150      1.079      1.226
  PC-1, HOMA-IR index                 0.004     1.225      1.066      1.407      0.001   1.308      1.131      1.513      0.001   1.359      1.159      1.593
  IL-10, IL-18, PC-1                  0.001     1.004      1.001      1.006      0.257   1.001      0.999      1.003      0.055   1.002      1.000      1.005
  IL-10, IL-18, PC-1, HOMA-IR index   0.002     1.003      1.001      1.004      0.013   1.002      1.000      1.003      0.001   1.003      1.001      1.005

Abbreviations: CI, confidence interval; OR, odds ratio.

Discussion {#s4}
==========

NAFLD is a silent disease influencing the Egyptian population. Numerous risk factors have been suggested in NAFLD pathogenesis, including advanced age, obesity, IR and hyperlipidemia, beside the roles of pro- and anti-inflammatory cytokines.[@b3],[@b10]

The results from the current study revealed that the risk of NAFLD development rises with increasing age. These results confirm the finding of Mahmoud *et al*.,[@b1] who reported that age is an independent risk factor for developing more severe NAFLD. This finding may be attributed to increased fat accumulation that occurs in liver with advancing age.

In a previous study, Ezzat and colleagues[@b18] found that abdominal adipose tissue comprises SCF and VF, which are considered as distinct anatomic depots. SCF varies from VF in that venous drainage from SCF is directed into the systemic circulation, while venous drainage from VF is directed into the portal vein directly to the liver; thus, the metabolic products reach the liver directly and exercise a first-pass influence on liver metabolism. Multivariate analysis in the current study showed that SCF and VF were significantly associated (*p* \<0.01) with grades 1, 2 and 3 ([Table 7](#t07){ref-type="table"}), this is due to the significant increase in SCF and VF in parallel with NAFLD grades; besides, SCF and VF showed high sensitivity and specificity in differentiating between grade 3, grade 2 and grade 0 (controls) and in differentiating between grade 2, grade 1 and grade 3. Moreover, VF showed high sensitivity and specificity in differentiating between grade 2 and grade 1.

In agreement with previous findings, it has been suggested that visceral fat releases adipokines and free fatty acids, leading to fat accumulation inside liver.[@b18] Our results showed that size of the liver was significantly increased in parallel with NAFLD grades, also spleen size was significantly higher in all NAFLD grades than in grade 0, but stayed within the average (11 cm).[@b29] So, our NAFLD patients did not have splenomegaly or non-cirrhotic portal hypertension. Furthermore, our study showed that liver size and spleen size have high sensitivity and specificity in differentiating between grade 3, grade 2 and grade 0 and in differentiating between grade 2 and grade 1, but only liver size could differentiate between grade 2, grade 1 and grade 3. To differentiate between grade 1 and grade 0, only spleen size could be used due to its having the highest sensitivity and specificity. This is in agreement with the report by Mahmoud *et al*.,[@b1] which stated that the sizes of liver and spleen were significantly higher in patients with steatosis than in non-steatosis patients.

Lipid profile parameters were significantly increased (except for HDL-cholesterol, which was decreased) in parallel with NAFLD grades. Moreover, cholesterol and LDL have high sensitivity and specificity in differentiating between grade 2, grade 1 and grade 0, but only cholesterol has high sensitivity and specificity in differentiating between grade 2 and grade 1. Triglycerides have high sensitivity and specificity in differentiating between all studied NAFLD grades except between grade 1 and grade 0. Furthermore, HDL has high sensitivity and specificity in differentiating between all studied NAFLD grades, except between grade 2 and grade 1. Multivariate analysis showed that cholesterol, HDL and LDL were significantly associated (*p* =0.001) with grades 1, 2 and 3, but triglycerides were significantly associated (*p*=0.001) with only grades 1 and 2. This is in agreement with the report by Mahmoud *et al*.,[@b1] which stated that hyperlipidemia was an independent predictor of NAFLD development. In contrast, Paredes-Turrubiarte *et al*.[@b30] reported no significant differences in the values of lipid profile when comparing all different NAFLD grades.

NAFLD is related to central obesity indices, one of which is WC. Central obesity contributes in causing IR, and increased visceral adiposity might be significant in NAFLD pathogenesis.[@b31] In our study, hip circumference showed gradual increase with increase of NAFLD grades. In addition, BMI and WC were significantly increased in parallel with NAFLD grades. This is in agreement with the report by Tominaga *et al*.,[@b5] which stated that BMI and WC were independent risk factors for NAFLD. Kim *et al*.[@b32] have also reported a significant association between the occurrence of fatty liver and its severity with an increase in BMI and WC. Multivariate analysis in our study showed that WC, hip circumference and waist to hip ratio were significantly associated with grades 1, 2 and 3, but surprisingly BMI was not associated (*p* \> 0.05) with all NAFLD grades ([Table 7](#t07){ref-type="table"}). Furthermore, WC, hip circumference and BMI showed high sensitivity and specificity in differentiating between NAFLD grades and grade 0 and in differentiating between grade 2 and grade 1. Only the waist to hip ratio and BMI showed high sensitivity and specificity for differentiating between grade 3 and grade 1.

The HOMA-IR index has been approved as an indicator of the insulin-resistant condition.[@b5] An upper boundary of normal HOMA-IR index is 1.5.[@b33] HOMA-IR index and insulin showed significant differences between NAFLD grades and controls in our study. All NAFLD patients in different grades showed HOMA-IR index value \>1.5, indicating that they are in an IR state, and this was confirmed by the multivariate analysis that showed the HOMA-IR index as being significantly associated (*p*= 0.001) with all NAFLD grades. However, the highest sensitivity and specificity of HOMA-IR index was found in differentiating between grade 3 and grade 0. This is in agreement with a report by Hegazy *et al*.,[@b31] which showed a direct association between insulin and HOMA-IR with NAFLD grades.

Obesity, defined as a condition of chronic low-grade inflammation caused by over-nutrition, is a main cause of NAFLD. Obesity causes lipid accumulation in adipocytes, which activates signaling pathways, thereby increasing the production of pro-inflammatory cytokines,[@b34] such as IL-18.[@b35] Meanwhile, anti-inflammatory protein expression (e.g. IL-10) decreases during weight gain and therefore causes fat mass expansion.[@b36] IL-18 was associated only with grade 3 in our study (OR = 1.1, 95%CI: 1.02-1.26, *p* \< 0.05). Furthermore, IL-18 has high sensitivity and specificity in differentiating between grade 1 and grade 0 and in differentiating between grade 3 and grade 2. The results of the IL-18 mean value in grade 3 showed significant increase in comparison with other grades due to the fact that grade 3 patients had more IR than the other NAFLD grades. This is in accordance with a report by Wang *et al*.,[@b37] which stated that IL-18 may contribute to the development of NAFLD by causing IR. In an insulin-resistant state, the incapability of insulin to inhibit lipolysis leads to raised fluctuation of free fatty acids to the liver from adipose tissue. Enlarged de novo lipogenesis and augmented consumption of dietary fat contribute to the development of NAFLD.[@b38] Li *et al*.[@b15] found that IL-18 was significantly higher in NAFLD patients than in controls, while Vecchiet *et al*.[@b14] reported that IL-18 plasma levels were not significantly increased in NAFLD patients compared to controls. However, Tapan *et al*.[@b16] did not find any significant differences regarding the IL-18 plasma concentrations between patients with NASH and simple steatosis.

In our study, IL-10 was associated only with grade 1 (OR = 1.5, 95%CI: 1.1-1.9, *p* \< 0.01);this is due to the fact that IL-10 mean value in grade 1 showed significant increase when compared to grade 0. The increase itself may be due to an IL-10 compensatory reaction for pro-inflammatory activation as found in healthy subjects.[@b39] Since HOMA-IR values in grade 2 and grade 3 were significantly higher than in grade 1, IL-10 was decreased in grade 2 and grade 3 compared to grade 1; this finding confirmed the insulin-sensitizing effects of IL-10.[@b9] The current results are in agreement with those reported by Paredes-Turrubiarte *et al*.,[@b30] namely the pronounced reduction in IL-10 that was demonstrated in severe NAFLD when compared to mild NAFLD, supporting a role for inflammatory mediators in promoting steatosis progression. Unfortunately, IL-10 failed in differentiating between NAFLD grades due to its low sensitivity (≤80%).

In our study, PC-1 levels were significantly higher in grade 1 patients; with low IR (HOMA-IR index =1.99) compared to grade 3 patients, who showed high IR (HOMA-IR index=2.82). This finding is in agreement with those reported by Frittitta *et al*.,[@b40] namely the decreased PC-1 levels demonstrated in insulin-resistant subjects compared to insulin-sensitive non-diabetic subjects. The reason for PC-1 decrease in grade 3 is that in insulin-resistant subjects, circulating PC-1 is cleared at a higher rate from plasma (either bound or degraded).[@b40] PC-1 levels were also higher in grade 1 patients than grade 0 patients, who were in an insulin-sensitive state, this may be due to the HOMA-IR index value not being significantly higher in grade 1 (1.99) compared to grade 0 (1.3). Furthermore, PC-1 has high sensitivity and specificity in differentiating between all studied NAFLD grades, except between grade 1 and grade 0.

Multivariate analysis showed that IL-10, IL-18 and PC-1 when combined with HOMA-IR index were associated with different NAFLD grades (grade 1, grade 2, grade 3) ([Table 7](#t07){ref-type="table"}). This is attributed to their important effects on the insulin signaling pathway.[@b9],[@b11],[@b37]

Conclusions {#s4-1}
-----------

-   BMI could differentiate between all different studied NAFLD grades, except between grade 3 and grade 2. WC and hip circumference could differentiate between all different studied NAFLD grades, except between grade 3 and grades 1 and 2, but only waist to hip ratio could differentiate between grade 3 and grade 1.

-   Ultrasonographic findings and lipid profile could differentiate between grade 2 and grade 0. Ultrasonographic findings, triglycerides and HDL could differentiate between grade 3 and grade 0. Ultrasonographic findings (except for SCF), cholesterol and triglycerides could differentiate between grade 2 and grade 1. Ultrasonographic findings (except for spleen size), triglycerides and HDL could differentiate between grade 3 and grades 1 and 2. Spleen size and lipid profile (except for triglycerides) could differentiate between grade 1 and grade 0.

-   IL-18 might differentiate between grade 1 and grade 0 and differentiate between grade 3 and grade 2. PC-1 could differentiate between all different studied NAFLD grades, except between grade 1 and grade 0.

-   HOMA-IR index could differentiate between grade 3 and grade 0.

-   Finally, the studied parameters could differentiate between the different grades to a certain extent. It is better to use these findings together with ultrasonography.

### Limitations of the study {#s4-1-1}

1.  The small size of this study was due to the cost of kits for the biochemical investigations; we recommend to increase the number of patients in future studies.

2.  In our study, we searched for cytokines that are related to the wide spectrum of NAFLD, which ranges from simple steatosis to NASH. We did not aim to focus on NASH cases in our study, since diagnosis for liver fibrosis or hepatocellular injury is invasive and very expensive.

3.  Although abdominal ultrasonography has low sensitivity for detecting mild NAFLD, as reported in previous literature, it is the best low-cost method available that is also a non-invasive technique for detecting NAFLD. Because of ethical considerations, we did not carry out a liver biopsy (none of our patients had clinical presentation or significant elevation in liver enzymes). Moreover, our studied patients considered themselves healthy and refused to undergo further invasive techniques, such as pathological examinations for liver biopsy to detect fibrosis, and our enrolled controls were selected carefully and did not show any risk factor for NAFLD development.
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